Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr Grieb on the Importance of Targeting the MYC Oncogene in CRC and Solid Tumors

May 22nd 2023

Brian C. Grieb, MD, PhD, emphasizes the importance of investigating agents that target the MYC oncogene, as well as supportive cofactors, in colorectal cancer and other tumor types.

Dr Hays on the Evolution of Later-line Treatment Options in Refractory mCRC

May 19th 2023

John L. Hays, MD, PhD, discusses the evolution of the treatment paradigm for patients with metastatic colorectal cancer who experience disease progression following standard chemotherapy regimens.

Dr Grieb on MYC in CRC

May 18th 2023

Brian C. Grieb, MD, PhD, discusses historical barriers to targeting the MYC oncogene in patients with colorectal cancer and the rationale for an ongoing phase 1/2 clinical trial that may demonstrate an effective way to target MYC in CRC and other solid tumors. 

Encorafenib Plus Cetuximab/Binimetinib Displays Activity, Safety in BRAF V600E–mutant mCRC

May 17th 2023

Triplet therapy consisting of encorafenib, cetuximab, and binimetinib demonstrated activity and manageable safety as first-line treatment for patients with BRAF V600E–mutated metastatic colorectal cancer.

Dr Muslimani on Unanswered Questions to be Addressed in HER2+ mCRC

May 17th 2023

Alaa Muslimani, MD, discusses unanswered questions in the treatment of patients with metastatic colorectal cancer, highlighting how these unmet needs may be addressed through continued research.

Understanding Lynch Syndrome and Associated Cancer Risk: Identification

May 17th 2023

In this third episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, discusses testing guidance for identifying Lynch syndrome.

Preliminary Data Show Improved Responses with Cetuximab Plus Divarasib in KRAS G12C–mutated CRC

May 16th 2023

Jayesh Desai, MBBS, FRACP, reports prior phase 1 data on the use of divarasib monotherapy in KRAS G12C–mutated CRC and early efficacy, safety, and presents pharmacokinetic data from the use of divarasib plus cetuximab from a phase 1 trial.

​​Dr Byndloss on the Relationship Between Gut Health and the Risk of Developing CRC

May 16th 2023

Mariana X. Byndloss, DVM, PhD, discusses the relationship between the gut microbiome and the risk of developing cancers such as colorectal cancer.

IBI351 Receives Breakthrough Therapy Designation in China for Previously Treated Advanced CRC

May 16th 2023

China’s National Medical Products Administration has granted a breakthrough therapy designation to the KRAS G12C inhibitor IBI351 as monotherapy for previously treated patients with advanced colorectal carcinoma harboring a KRAS G12C mutation.

Understanding Lynch Syndrome and Associated Cancer Risk: Epidemiology

May 10th 2023

In this second episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, delves into the epidemiology of Lynch syndrome, the pathogenic variants in the mismatch-repair genes that cause the condition, and criteria utilized to identify it.

Continued Development of Targeted Therapies Aims to Address Unmet Needs in CRC

May 9th 2023

John L. Marshall, MD, discusses the identification of targetable subsets of patients with advanced CRC, unmet needs that remain to be addressed for patients with advanced CRC, and the continued need for a multidisciplinary approach in treating patients across the gastrointestinal cancer spectrum.

Dr Murciano-Goroff on the Evaluation of LY3537982 in KRAS G12C–Mutated NSCLC, CRC and Other Solid Tumors

May 5th 2023

Yonina R. Murciano-Goroff, MD, MSc, DPhil, discusses the evaluation of LY3537982 in patients with KRAS G12C–mutated non–small cell lung cancer, colorectal cancer, and other solid tumors.

Audience Q&A: Best Practices in Managing HER2-Amplified CRC

May 5th 2023

Fielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.

Dr Kopetz on the Rationale of the BREAKWATER Study in BRAF V600E­mutant mCRC

May 4th 2023

Scott Kopetz, MD, PhD, FACP, discusses the rationale for launching the phase 3 BREAKWATER trial in BRAF V600E­–mutant metastatic colorectal cancer.

Dr Bloomer on HRQOL Outcomes in Younger and Older Patients in CRC

May 3rd 2023

Amanda Bloomer, PhD, discusses the comparison of health-related quality of life outcomes between younger and older adult patients with newly diagnosed colorectal cancer evaluated in the ColoCare study.

IMX-110 Plus Tislelizumab Shows Early Activity in Advanced Metastatic Colorectal Cancer

May 3rd 2023

Treatment with the combination of IMX-110 and tislelizumab resulted in 100% tumor shrinkage at 2 months in 2 of 2 evaluable patients with advanced metastatic colorectal cancer who received the regimen at the lowest dose level examined in the dose-escalation portion of the ongoing phase 1b/2a IMMINENT-01 trial

Dr Hays on the Significance of the Tucatinib/Trastuzumab Approval in HER2-Positive mCRC

May 3rd 2023

John L. Hays, MD, PhD, discusses the significance of the approval for tucatinib and trastuzumab for patients with HER2-expressing metastatic colorectal cancer.

Understanding Lynch Syndrome and Associated Cancer Risk: Prevalence

May 3rd 2023

In this first episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, provides a brief overview of Lynch syndrome and its prevalence in the United States and beyond.

Dr Murciano-Goroff on the Investigation of KRAS G12C Inhibitor LY3537982 in Solid Tumors

April 28th 2023

Yonina R. Murciano-Goroff, MD, MSc, DPhil, discusses the investigation of the novel KRAS G12C inhibitor LY3537982 in patients with non–small cell lung cancer, colorectal cancer, and other solid tumors.

Evolutions in the HER2-Amplified CRC Treatment Landscape

April 28th 2023

Looking toward the future management of HER2-amplified colorectal cancer, panelists reflect on ongoing clinical trials and evolving treatment strategies.

NEXT PAGE
PREVIOUS PAGE